Graphene Investments SAS Sells 2,800 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Graphene Investments SAS decreased its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 10.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 24,200 shares of the specialty pharmaceutical company’s stock after selling 2,800 shares during the period. Jazz Pharmaceuticals accounts for about 2.1% of Graphene Investments SAS’s holdings, making the stock its 20th biggest holding. Graphene Investments SAS’s holdings in Jazz Pharmaceuticals were worth $2,980,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in JAZZ. UMB Bank n.a. grew its holdings in Jazz Pharmaceuticals by 70.9% during the 4th quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company’s stock worth $38,000 after acquiring an additional 129 shares during the period. GAMMA Investing LLC increased its holdings in Jazz Pharmaceuticals by 41.3% in the third quarter. GAMMA Investing LLC now owns 414 shares of the specialty pharmaceutical company’s stock worth $46,000 after purchasing an additional 121 shares in the last quarter. Itau Unibanco Holding S.A. lifted its stake in Jazz Pharmaceuticals by 63.2% in the third quarter. Itau Unibanco Holding S.A. now owns 444 shares of the specialty pharmaceutical company’s stock valued at $49,000 after buying an additional 172 shares during the period. Venturi Wealth Management LLC boosted its holdings in shares of Jazz Pharmaceuticals by 577.0% during the 3rd quarter. Venturi Wealth Management LLC now owns 826 shares of the specialty pharmaceutical company’s stock worth $92,000 after buying an additional 704 shares in the last quarter. Finally, Versant Capital Management Inc grew its position in shares of Jazz Pharmaceuticals by 56.7% during the 4th quarter. Versant Capital Management Inc now owns 967 shares of the specialty pharmaceutical company’s stock worth $119,000 after buying an additional 350 shares during the period. 89.14% of the stock is currently owned by institutional investors.

Jazz Pharmaceuticals Stock Performance

JAZZ stock opened at $120.07 on Friday. The business has a 50 day moving average of $122.60 and a 200-day moving average of $116.32. The firm has a market cap of $7.26 billion, a PE ratio of 16.91, a P/E/G ratio of 0.90 and a beta of 0.56. Jazz Pharmaceuticals plc has a 12-month low of $99.06 and a 12-month high of $134.17. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46.

Insider Buying and Selling at Jazz Pharmaceuticals

In related news, CEO Bruce C. Cozadd sold 1,500 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $123.43, for a total value of $185,145.00. Following the sale, the chief executive officer now owns 425,525 shares of the company’s stock, valued at approximately $52,522,550.75. The trade was a 0.35 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders sold 5,053 shares of company stock worth $617,442 in the last quarter. 4.20% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

JAZZ has been the topic of several research analyst reports. HC Wainwright reissued a “buy” rating and set a $200.00 target price on shares of Jazz Pharmaceuticals in a research note on Friday, November 22nd. Royal Bank of Canada reissued an “outperform” rating and set a $179.00 price objective on shares of Jazz Pharmaceuticals in a research report on Tuesday, December 10th. Morgan Stanley raised Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $140.00 to $175.00 in a research report on Thursday, December 12th. TD Cowen cut their price target on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a report on Thursday, November 7th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $163.00 target price on shares of Jazz Pharmaceuticals in a research report on Thursday, December 12th. Two investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Jazz Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $177.00.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.